Emergency Filtration Products Inc. Announces CPR Mask White Paper Complete and Available.

LAS VEGAS--(BUSINESS WIRE)--April 28, 1999--

Emergency Filtration Products Inc. (EFP) (OTC BB:EMFP) Wednesday announced that what is believed to be the first white paper ever to be done on CPR masks is now complete and available for review.

The paper is based on data gathered from results of independent laboratory testing of the three best-selling CPR masks on the market today and EFP's mask, RespAide.

EFP President Michael J. Crnkovich said: "CPR is a tool which is only used in life-and-death situations. Therefore, we believe that those who either assume responsibility or are charged with responsibility for another human being's life should have access to all relevant data. This being the case, we are making the study available to any and all interested parties."

Copies of EFP's white paper can be obtained through mail, fax or e-mail by calling 888/656-3697.

Emergency Filtration Products holds U.S. and international patents on its flagship product, RespAide, and on its filtering technology. RespAide is the only CPR mask to be awarded a Food and Drug Administration 510K number and has obtained military stocking numbers.

RespAide is designed to protect both patient and rescuer from bacterial and viral infections -- such as HIV, hepatitis C, tuberculosis and other communicable diseases -- during mouth-to-mouth resuscitation. Independent laboratory tests show RespAide's bacterial and viral filtration efficiencies to be "greater than 99.9 percent."

RespAide is distributed by Bergen Brunswig (NYSE:BBC), Preferred Health Technologies, ProMedix Inc. and other medical-supply companies in the United States. International distributors include Renalife SA and Roemmer's Pharmaceuticals in South America, UniSource in Europe, Asia World Medical Technologies in Asia and Einat Medical in Israel.